Latest News for: ptk7

Edit

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting ...

Rio Grande Sun 02 Dec 2025
B7H3 and PTK7 is co-expressed in multiple solid tumor ...
Edit

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

PR Newswire 01 Dec 2025
Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to evaluate IDE034, a potential first-in-class bispecific B7H3/PTK7 TOP1 antibody-drug conjugate (ADC).
Edit

Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across ...

The Berkshire Eagle 25 Oct 2025
PTK7 is the third most highly expressed tumor marker among clinically validated and emerging ADC targets, present in ~70% of tumors ....
Edit

Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC

PR Newswire 24 Oct 2025
PTK7 is the third most highly expressed tumor marker among clinically validated and emerging ADC targets, present in ~70% of tumors. PTK7 expression is stable ... There are no approved PTK7-directed ADCs.
  • 1

Article Search

tools
×
×
×
×